¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"vitreous loss"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • vitreous opacity
    À¯¸®Ã¼È¥Å¹
  • vitreous separation
    À¯¸®Ã¼ºÐ¸®
  • vitreous syneresis
    À¯¸®Ã¼¾×È­
  • vitreous tap
    À¯¸®Ã¼ÃµÀÚ
  • audiometric hearing loss
    û·Â¼Ò½Ç
  • abrasion loss
    ¸¶¸ê·®, ¸¶¸ð·®
  • allowable blood loss
    Çã¿ë½ÇÇ÷·®, Çã¿ëÇ÷¾×»ó½Ç·®
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • conductive hearing loss
    ÀüÀ½³­Ã», Àüµµ³­Ã»
  • congenital hereditary hearing loss
    ¼±ÃµÀ¯Àü³­Ã»
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • central hearing loss
    ÁßÃßû·Â¼Ò½Ç, ÁßÃß³­Ã»
  • functional hearing loss
    ±â´É³­Ã»
  • familial progressive hearing loss
    °¡Á·¼ºÁøÇ೭û
  • hearing loss
    ³­Ã», û·Â¼Ò½Ç, û·ÂÀå¾Ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • vitreous opacity
    À¯¸®Ã¼È¥Å¹
  • vitreous separation
    À¯¸®Ã¼ºÐ¸®
  • vitreous strand
    À¯¸®Ã¼°¡´Ú
  • vitreous syneresis
    À¯¸®Ã¼¾×È­
  • vitreous tap
    À¯¸®Ã¼ÃµÀÚ
  • vitreous
    À¯¸®Ã¼-, À¯¸®Ã¼
  • abrasion loss
    ¸¶¸ê·®, ¸¶¸ð·®
  • allowable blood loss
    Çã¿ë½ÇÇ÷·®
  • audiometric hearing loss
    û·Â¼Ò½Ç
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • central hearing loss
    ÁßÃßû·Â¼Ò½Ç, ÁßÃß³­Ã»
  • condensed milk conductive hearing loss
    ³óÃà¿ìÀ¯ÀüµµÃ»°¢¼Ò½Ç
  • conductive hearing loss
    Àüµµ³­Ã»
  • conductive hearing loss
    ÀüÀ½¼º³­Ã»
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hearing loss, conductive
    ÀüÀ½¼º ³­Ã», Àüµµ¼º ³­Ã»
  • hearing loss, congenital hereditary
    ¼±Ãµ(¼º) À¯Àü¼º ³­Ã»
  • hearing loss, familial pregressive
    °¡Á· ÁøÇà(¼º) ³­Ã»
  • hearing loss, functional
    ±â´É(¼º) ³­Ã»
  • hearing loss, idiopathic sudden
    Ư¹ß¼º µ¹¹ß(¼º)³­Ã»
  • hearing loss, mixed
    È¥ÇÕ(¼º) ³­Ã»
  • hearing loss, noise induced
    ¼ÒÀ½¼º³­Ã»
  • hearing loss, occupational
    Á÷¾÷¼º³­Ã»
  • hearing loss, perceptive
    °¨À½³­Ã»
  • hearing loss, sensorineural
    °¨°¢½Å°æ¼º ³­Ã»
  • hearing loss, speech
    ¾îÀ½Ã»·Â¼Õ½Ç
  • heat loss
    ¿­¼Õ½Ç(ËçËÛËà).
  • heating loss
    °¡¿­°¨·®(¡­ÊõåÖ).
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
  • idiopathic sudden hearing loss
    Ư¹ß¼º µ¹¹ß(¼º)³­Ã»
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • conductive hearing loss
    ÀüÀ½¼º Àüµµ¼º ³­Ã»
  • congenital hearing loss
    ³­Ã»
  • corpus vitreum =vitreous body<³ª>
    À¯¸®Ã¼, ÃÊÀÚü(õ¦í­ô÷).
  • discrimination loss
    ¾îÀ½ÆÇº°¼Õ½Ç
  • economic loss
    °æÁ¦Àû ¼Õ½Ç.
  • evaporation loss
    Áõ¹ß¼Õ½Ç(¡­áßã÷).
  • functional hearing loss
    ±â´É(¼º) ³­Ã»
  • gastrointestinal loss
  • hearing loss
    °¨°¢½Å°æ(¼º) ³­Ã»
  • hearing loss
    ³­Ã», û·Â¼Ò½Ç, û·ÂÀå¾Ö
  • hearing loss, audiometric
    û·Â¼Õ½Ç
  • hearing loss, central
    ÁßÃß¼º û·Â¼Ò½Ç, ÁßÃß¼º ³­Ã»
  • hearing loss, conductive
    ÀüÀ½¼º ³­Ã», Àüµµ¼º ³­Ã»
  • hearing loss, congenital hereditary
    ¼±Ãµ(¼º) À¯Àü¼º ³­Ã»
  • hearing loss, familial pregressive
    °¡Á· ÁøÇà(¼º) ³­Ã»
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
UGH+ uveitis-glaucoma-hyphema plus vitreous hemorrhage [syndrome]
VF left leg [electrode]; ventricular fibrillation; ventricular fluid; ventricular flutter; visual field...
VISC vitreous infusion suction cutter
LOC Loss Of Consciousness
ABCDES abnormal alignment, bones-periarticular osteoporosis, cartilage-joint space loss, deformities, margi...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ABL Alveolar bone loss
CLV Corrected Loss Variance
EELS Electron Energy Loss Spectroscopy
EBL Estimated blood loss
EWL Evaporative water loss
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • loss of appetite
    ½Ä¿å ºÎÁø
  • loss of consciousness
    ÀÇ½Ä »ó½Ç
  • loss of gloss
    ±¤ÅÃÀÇ ¼Ò½Ç
  • loss of molar support
    ±¸Ä¡ºÎ ÁöÁöÀÇ »ó½Ç
  • loss of structural integrity
    ±¸Á¶ÀûÀÎ ¿ÏÀü¼ºÀÇ »ó½Ç
  • patchy loss
    ¹Ý¼º »ó½Ç
  • sensorineural hearing loss
    °¨°¢ ½Å°æ¼º ³­Ã»
  • sensory hearing loss
    °¨°¢¼º ³­Ã»
    ¿Í¿ì
  • signal loss
    ½ÅÈ£ ¼Ò½Ç
  • weight loss
    üÁß °¨¼Ò
    ´Ü½Ä, ½ÄÀÌÁ¶Àý, º´À¸·Î ÀÎÇØ ³ªÅ¸³ª¸ç, üÁö¹æÀÇ °¨¼Ò ¶Ç´Â À½½Ä¼·Ãë ºÎÁ·À¸·Î ÀÎÇÑ ¿µ¾ç°áÇÌ ½Ã¿¡ ³ªÅ¸³­´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
persistent posterior hyperplastic primary vitreous A unilateral congenital anomaly in full-term infants; associated with a congenital retinal fold and a vitreous membranous stalk containing remnants of the hyaloid artery.
(05 Mar 2000)
coloboma of vitreous A congenital indentation of the vitreous body by mesoderm; associated with severe myopia.
(05 Mar 2000)
primary vitreous The vitreous first formed in the embryo between the optic cup and the lens vesicle, and later vascularised by the hyaloid artery and its branches.
(05 Mar 2000)
secondary vitreous Avascular vitreous formed around the primary vitreous.
(05 Mar 2000)
stroma of vitreous The delicate framework of the vitreous body embedded in or enclosing the vitrous humor.
Synonym: stroma vitreum.
(05 Mar 2000)
tertiary vitreous Vitreous fibrils derived from the neuroepithelium of the ciliary body and forming the ciliary zonule.
(05 Mar 2000)
alveolar bone loss The resorption of bone in the supporting structures of the maxilla or mandible as a result of periodontal disease.
(12 Dec 1998)
axon loss polyneuropathy A type of polyneuropathy in which axon degeneration is the sole/predominant feature; many aetiologies, particularly toxic and metabolic; on nerve conduction studies, affects amplitudes of the responses, but does not cause conduction slowing or block.
Synonym: axonal polyneuropathy.
(05 Mar 2000)
blood loss, surgical Loss of blood during surgery.
(12 Dec 1998)
Parallel Electron Energy Loss Spectroscopy <technique> Electron energy loss spectroscopy analyses the inelastically scattered electrons present in the beam after it has been transmitted through the sample. An electron energy loss spectrum typically consists of a monatomic decreasing background on which are superimposed a number of peaks. Each peak is characteristic of the scattering process that has occurred in the sample. The peaks can be used to obtain information about the chemical composition and electronic structure of the sample. Electron energy loss spectra are acquired typically in a magnetic sector spectrometer located under the camera chamber of the transmission electron microscope. Spatial resolution is typically limited by the minimum probe diameter of the microscope. Electron energy loss spectroscopy tends to be complimentary to EDS in that it can be used to analyse very thin samples of low Z materials.
Acronym: PEELS
(05 Aug 1998)
periodontal attachment loss Loss or destruction of periodontal tissue caused by periodontitis or other destructive periodontal diseases or by injury during instrumentation. Attachment refers to the periodontal ligament which attaches to the alveolar bone. It has been hypothesised that treatment of the underlying periodontal disease and the seeding of periodontal ligament cells enable the creating of new attachment.
(12 Dec 1998)
water loss, insensible Loss of water by diffusion through the skin and by evaporation from the respiratory tract. It is so called because we do not know that we are actually losing water at the time that it is leaving the body. (guyton, textbook of medical physiology, 8th ed, p274)
(12 Dec 1998)
weight loss Decrease in existing body weight.
(12 Dec 1998)
conductive hearing loss <otolaryngology> A form of deafness that results from a blockage of the ear canal or dysfunction of the ossicles or eardrum (sound collecting apparatus).
In conductive hearing loss the auditory nerve is normal, but there exists a physical problem with the sound collecting apparatus.
(05 Jan 1998)
hair loss Hair loss may be associated with aging, hormones (androgens) or genetic predisposition. The pattern of baldness in women is different from that of men. In women there is thinning of the hair all over the scalp, but the frontal hairline is maintained. The hair loss is usually permanent. Treatment has been successful with topical minoxidil in some cases.
(13 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á